Table 4. Strength of association between prognostic factors and recurrence free survival determined by Cox regression analysis (primary analysis population, n = 171).
| n | Hazard Ratio (95% CI) | p-value** | ||
|---|---|---|---|---|
| Single factor models | ||||
| HPV mRNA of SLN | negative | 119 | 1 | 0.004 |
| positive | 52 | 3.79 (1.54 – 9.27) | ||
| Tumor size [mm] | ≤ 20 | 92 | 1 | <0.001 |
| >20 to 40 | 58 | 9.20 (2.03 – 41.53) | ||
| >40 | 21 | 19.68 (4.08 – 94.80) | ||
| Histology | Squamous cell ca | 138 | 1 | 0.869 |
| Adenocarcinoma | 26 | 1.34 (0.44 – 4.03) | ||
| Others | 7 | 1.21 (0.15 – 9.13) | ||
| Grading* | G1 | 16 | 1 | 0.096 |
| G2 | 73 | 0.29 (0.06 – 1.29) | ||
| G3 | 76 | 0.96 (0.27 – 3.38) | ||
| Age [years] | 171 | 1.03 (1.00 – 1.07) | 0.050 | |
| Two factor models | ||||
| HPV mRNA of SLN | negative | 119 | 1 | 0.030 |
| positive | 52 | 2.79 (1.10 – 7.03) | ||
| Tumor size | ≤ 20 mm | 92 | 1 | 0.001 |
| >20 – 40 mm | 58 | 6.66 (1.43 – 30.99) | ||
| >40 mm | 21 | 17.77 (3.67 – 85.93) | ||
| HPV mRNA of SLN | negative | 119 | 1 | 0.004 |
| positive | 52 | 3.81 (1.55 – 9.38) | ||
| Histology | Squamous cell ca | 138 | 1 | 0.877 |
| Adenocarcinoma | 26 | 1.30 (0.43 – 3.92) | ||
| Others | 7 | 0.85 (0.11 – 6.47) | ||
| HPV mRNA of SLN* | negative | 113 | 1 | 0.009 |
| positive | 52 | 3.29 (1.34 – 8.08) | ||
| Grading* | G1 | 16 | 1 | 0.142 |
| G2 | 73 | 0.32 (0.07 – 1.42) | ||
| G3 | 76 | 0.95 (0.27 – 3.35) | ||
| HPV mRNA of SLN | negative | 119 | 1 | 0.005 |
| positive | 52 | 3.63 (1.48 – 8.89) | ||
| Age [years] | 171 | 1.03 (0.99 – 1.07) | 0.070 | |
Abbreviations: SLN – sentinel lymph node, CI – confidence interval, ca. – cancer
*
Valid datasets: Grading and related two factor model n = 165
**
Wald test